| Literature DB >> 29736381 |
P Annécie Benatrehina1, Li Pan1, C Benjamin Naman1, Jie Li1, A Douglas Kinghorn1.
Abstract
In view of the continuous growth of the botanical dietary supplement industry and the increased popularity of lesser known or exotic botanicals, recent findings are described on the phytochemical composition and biological activities of five selected fruits consumed in the United States, namely, açaí, noni, mangosteen, black chokeberry, and maqui berry. A review of the ethnomedicinal uses of these plants has revealed some similarities ranging from wound-healing to the treatment of fever and infectious diseases. Laboratory studies on açaí have shown both its antioxidant and anti-inflammatory activities in vitro, and more importantly, its neuroprotective properties in animals. Anthraquinones and iridoid glucosides isolated from noni fruit induce the phase II enzyme quinone reductase (QR), and noni fruit juice exhibited antitumor and antidiabetic activities in certain animal models. Antitumorigenic effects of mangosteen in animal xenograft models of human cancers have been attributed to its xanthone content, and pure α-mangostin was shown to display antineoplastic activity in mice despite a reported low oral bioavailability. Work on the less extensively investigated black chokeberry and maqui berry has focused on recent isolation studies and has resulted in the identification of bioactive secondary metabolites with QR-inducing and hydroxyl-radical scavenging properties. On the basis of the safety studies and toxicity case reports described herein, these fruits may be generally considered as safe. However, cases of adulteration found in a commercialized açaí product and some conflicting results from mangosteen safety studies warrant further investigation on the safety of these marketed botanical dietary supplements.Entities:
Keywords: Açaí; Black chokeberry; Mangosteen; Maqui berry; Noni
Year: 2018 PMID: 29736381 PMCID: PMC5934707 DOI: 10.1016/j.jtcme.2018.01.006
Source DB: PubMed Journal: J Tradit Complement Med ISSN: 2225-4110
Ethnomedicinal uses of açaí, noni, mangosteen, black chokeberry, and maqui berry.
| Botanical | Part used | Uses | Reference |
|---|---|---|---|
| Açaí | fruits | skin ulcers, influenza (juice), antidiarrheal (oil) | |
| seeds | febrifuge (infusion) | ||
| roots | jaundice, antimalarial, treatment of kidney diseases | ||
| Noni | fruits | mouth sores, toothaches, treatment of fever, diabetes, intestinal worms, fungal infections, tuberculosis | |
| leaves | cough, topical burns, rheumatic joints, ulcers | ||
| bark | urinary disorders, antihelmintic, stomachaches, antibacterial | ||
| roots | cancerous swellings, sore throat, febrifuge | ||
| Mangosteen | fruit pericarp | wound-healing, skin infections, diarrhea | |
| leaves and bark | eczema, psoriasis | ||
| Black chokeberry | fruits | common cold | |
| bark | astringent | ||
| not specified | antihypertensive, atherosclerosis, hemorrhoids | ||
| Maqui berry | fruits | dysentery, diarrhea, wound-healing | |
| leaves | sore throat, antitumor, fever | ||
| unspecified | stomach ulcer, kidney pain, antitumor, scars, hemorrhoids, diarrhea, migraines |
Highlights of in vitro bioactivity of açaí, noni, mangosteen, black chokeberry, and maqui berry.
| Botanical | Test sample | Cell line/bioassay | Results | Reference |
|---|---|---|---|---|
| Açaí | new neolignan glucosides ( | PMA-stimulated HL-60 human leukemia cells | antioxidant activity by blocking ROS production | |
| velutin ( | LPS-treated RAW-blue and RAW-264.7 murine macrophages, or C57BL/6 mouse peritoneal macrophages | anti-inflammatory activity: | ||
| fruit pulp extract and fractions | LPS-activated murine BV-2 microglial cells | anti-inflammatory by inhibition of iNOS, p38-MAPK, TNF-α, NF-κB, and COX-2 production | ||
| Noni | pure Costa Rican noni juice | LPS-activated J774 macrophages, ovine COX-1 and -2 | moderate reduction of NO and PGE2 production, and inhibition of COX-1 and -2 | |
| americanin A ( | MRC-5 normal human lung epithelial cells | no toxicity in normal cells (IC50 > 100 μM) | ||
| Mangosteen | α-mangostin | DMBA-induced preneoplastic mouse mammary glands | inhibition of preneoplastic lesions (IC50 = 2.4 μM) | |
| Black chokeberry | hyperin ( | hydroxyl-radical scavenging assay | antioxidant activity (ED50 = 0.17–0.75 μM) | |
| protecatechuic acid ( | murine hepa1c1c7 | induction of quinone reductase phase II enzyme (CD = 3.1–8.8 μM) | ||
| Maqui berry | fruit methanol extract | DPPH and ABTS radical scavenging assay, FRAP and FIC activity assays | antioxidant activity 28, 19, 25 g TE/kg (for DPPH, ABTS, and FRAP) and 0.12 g EDTAE/kg (FIC) |
PMA: phorbol 12-myristate-13-acetate. ROS: reactive oxygen species. LPS: lipopolysaccharides. SEAP: secreted embryonic alkaline phosphatase; DMBA: 7,12-dimethylbenz[α]anthracene; DPPH: (2,2-diphenyl-1-picrylhydrazyl); ABTS: 2,2- azino-bis(3-ethylbenzothyazolin-6-sulfonic ammonium)-salt; FRAP: ferric reducing antioxidant power; FIC: ferrous ion chelating.
Examples of in vivo bioactivity studies of açaí, noni, mangosteen, black chokeberry, and maqui berry.
| Botanical | Test sample/compound | Animal model | Delivery route/dose/duration | Outcome | Reference |
|---|---|---|---|---|---|
| Açaí | freeze-dried açaí powder | 19-month old Fischer rats (n = 15–20/group) | oral, ad libitum (2% of diet for 6–7 weeks) | increased production of antioxidant marker Nrf2 in hippocampus and frontal cortex | |
| Noni | fermented fruit exudates and fractions | S180 sarcoma tumor-challenged C57BL/6J mice (n = 4–8/group) | oral, ad libitum (0.2 mL i.p. or 5% of drinking water 3d-4 weeks) | inhibition of tumor development and suppression of existing tumor cells | |
| Tahitian Noni® juice | MMTV-neu transgenic mice (n = 30–45/group) | oral, ad libitum (10% v/v drinking water, maximum 14 months) | reduction of mammary tumor growth but not incidence | ||
| pure Costa Rican noni juice | carrageenan-induced acute paw edema rat model (n = 8/group) | by gavage (14.8 and 37 mg/kg, one time) or i.p. (7.4 and 37 mg/kg, one time) | reduction of acute and chronic inflammation | ||
| asthmatic rat model (ovalbumin-induced, n = 8/group) | oral (4.6 mL/kg) and i.p. (2.3 mL/kg) (7 days) | reduced number of inflammatory cells in bronchoalveolar lavage | |||
| americanin A (11) | HCT116 tumor xenograft mice (n = 6/group) | i.p. (5 or 10 mg/kg, 3 times/week for 41 days) | tumor volume reduction by 45%–56% | ||
| Mangosteen | α-mangostin | HT-29 human colon xenograft mice (n = 18/group) | oral, ad libitum (900 mg/kg added to diet, 3 weeks) | attenuation of tumor growth, and reduction of apoptotic proteins (BcL-2 and β-catenin) concentrations in tumor mass | |
| Black chokeberry | CellBerry® (spray-dried fruit extract) | Rats fed fructose-rich diet (n = 6/group) | oral, ad libitum (100 or 200 mg/kg BW/d added to drinking water, 6 weeks) | reduced cholesterol, blood glucose modulation of adipogenesis and insulin signaling pathways | |
| Commercial spray-dried fruit ethanol extract | apolipoprotein E knockout mice fed high-fructose diet (n = 10/group) | oral, ad libitum (0.005 or 0.05% diet, 4 weeks) | reduction of plasma cholesterol improved hepatic and plasma antioxidant function | ||
| Maqui berry | fruit methanol extract | ischemia/reperfusion rat model | i.p. (10 mg/kg, single dose) | cardioprotective effect | |
| anthocyanin-rich fraction of methanol fruit extract | obese hyperglycemic mice (n = 4–10/group) | by gavage (50–500 mg/kg single doses) | reduction of blood glucose levels and improved glucose tolerance |
Fig. 1Structures of representative compounds isolated from Euterpe oleracea.
Fig. 2Structures of representative compounds isolated from Morinda citrifolia.
Fig. 3Structures of representative compounds isolated from Garicinia mangostana.
Fig. 4Structures of representative compounds isolated from Aronia melanocarpa.
Fig. 5Structures of representative compounds isolated from Aristotelia chilensis.